News

FDA’s arthritis advisory committee unanimously backs biosimilar Humira


 

References

In a 26-0 vote, the Food and Drug Administration’s arthritis advisory committee recommended July 12 that the agency license an Amgen product as biosimilar to Humira (adalimumab) for seven distinct indications: rheumatoid arthritis, juvenile idiopathic arthritis (in patients at least 4 years old), psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, adult Crohn’s disease, and adult ulcerative colitis.

Developing Story

Recommended Reading

Immunosuppressive regimens did not affect risk of cancer recurrence in meta-analysis
MDedge Internal Medicine
Obesity may attenuate anti-TNF response in psoriatic arthritis
MDedge Internal Medicine
Actemra may reduce scleroderma skin thickening
MDedge Internal Medicine
NSAID plus TNFi linked to less ankylosing spondylitis progression
MDedge Internal Medicine
NSAID plus TNFi linked to less ankylosing spondylitis progression
MDedge Internal Medicine
Pharma jousts statistically for an ankylosing spondylitis edge
MDedge Internal Medicine
HCQ eye toxicity needs experience to assess
MDedge Internal Medicine
New fragility fracture recommendations emphasize coordination of care
MDedge Internal Medicine
JAK-1 inhibitors heading for validation in phase III trials
MDedge Internal Medicine
Etanercept biosimilar proves effective, tolerated in phase III trial
MDedge Internal Medicine